Hypoxia-driven lncRNA SHIELD promotes GPX4 translation and protects against ferroptosis in hepatocellular carcinoma

  • Mol Cell. 2026 Jun 4;86(11):2106-2123.e8. doi: 10.1016/j.molcel.2026.04.026.
Kejia Liu  1 Ying Liu  1 Rick F Thorne  2 Fanzheng Meng  3 Yao Liu  4 Mian Wu  5 Lianxin Liu  6
Affiliations
  • 1. Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Provincial Key Laboratory of Hepatopancreatobiliary Surgery, Hefei 230001, China; Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei 230001, China.
  • 2. Translational Research Institute, Henan Provincial People's Hospital, Zhengzhou 450053, China.
  • 3. Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Provincial Key Laboratory of Hepatopancreatobiliary Surgery, Hefei 230001, China; Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei 230001, China. Electronic address: [email protected].
  • 4. Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Provincial Key Laboratory of Hepatopancreatobiliary Surgery, Hefei 230001, China; Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei 230001, China. Electronic address: [email protected].
  • 5. Translational Research Institute, Henan Provincial People's Hospital, Zhengzhou 450053, China. Electronic address: [email protected].
  • 6. Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Anhui Provincial Key Laboratory of Hepatopancreatobiliary Surgery, Hefei 230001, China; Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei 230001, China. Electronic address: [email protected].
Abstract

Targeting Ferroptosis, a form of regulated cell death, holds potential for improving treatment efficacy in a range of cancers including hepatocellular carcinoma (HCC). The selenoprotein Glutathione Peroxidase 4 (GPX4) plays a crucial role in suppressing Ferroptosis by converting toxic phospholipid hydroperoxides into non-toxic lipid alcohols, yet the mechanisms regulating its synthesis remain poorly understood. This study identifies SHIELD (suppressor of hypoxia-induced lipid peroxidation and death), a long noncoding RNA (lncRNA) and direct HIF-1α target, as a regulator of Ferroptosis in HCC. SHIELD inhibits Ferroptosis by interacting with the RNA-binding protein GRSF1, which forms a ternary complex with GPX4 5'-UTR to enhance GPX4 mRNA translation and expression. Furthermore, targeting SHIELD with Antisense Oligonucleotides (ASOs) in combination with sorafenib significantly reduced tumor growth in patient-derived xenograft models. This discovery paves the way for improving the efficacy of tyrosine kinase inhibitors in HCC, which addresses the challenge of therapeutic resistance.

Keywords
GPX4; LncRNA; ferroptosis; hepatocellular carcinoma; translation.
Products
Inhibitors & Agonists
Other Products